^
Association details:
Biomarker:NRAS mutation
Cancer:Melanoma
Drug:SCH772984 (ERK inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
New
Source:
Title:

Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma

Excerpt:
SCH772984 is highly active amongst BRAF-mutant, NRAS-mutant, double mutant and double wild-type melanoma cell lines, and this drug potently inhibited some lines with innate resistance or acquired resistance to vemurafenib.
DOI:
10.1186/1476-4598-13-194